10x Genomics (TXG) Projected to Post Earnings on Thursday

10x Genomics (NASDAQ:TXG) is projected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect 10x Genomics to post earnings of ($0.2670) per share and revenue of $147.96 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.10. The company had revenue of $151.04 million for the quarter, compared to the consensus estimate of $146.67 million. 10x Genomics had a negative net margin of 12.18% and a negative return on equity of 9.33%. The company’s revenue for the quarter was down 12.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.28 earnings per share. On average, analysts expect 10x Genomics to post ($0.77) EPS for the current fiscal year and ($0.58) EPS for the next fiscal year.

10x Genomics Stock Up 5.9%

TXG opened at $65.29 on Wednesday. The firm has a market cap of $8.51 billion, a P/E ratio of -110.66 and a beta of 2.03. 10x Genomics has a 52 week low of $12.80 and a 52 week high of $102.81. The business’s fifty day simple moving average is $74.13 and its 200 day simple moving average is $40.99.

Insider Activity at 10x Genomics

In related news, CFO Adam Taich sold 46,388 shares of the business’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $64.57, for a total value of $2,995,273.16. Following the transaction, the chief financial officer owned 316,344 shares in the company, valued at approximately $20,426,332.08. The trade was a 12.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John R. Stuelpnagel sold 20,000 shares of the business’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $61.75, for a total value of $1,235,000.00. Following the completion of the transaction, the director owned 328,436 shares in the company, valued at approximately $20,280,923. This trade represents a 5.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 179,333 shares of company stock valued at $11,810,070. 8.84% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on TXG shares. TD Cowen increased their price target on shares of 10x Genomics from $47.00 to $70.00 and gave the stock a “hold” rating in a research note on Tuesday, October 13th. UBS Group started coverage on shares of 10x Genomics in a research note on Wednesday, September 9th. They set a “neutral” rating and a $68.00 price objective for the company. Piper Sandler upped their price objective on 10x Genomics from $47.00 to $80.00 and gave the stock a “neutral” rating in a report on Monday, September 28th. Citigroup increased their target price on 10x Genomics from $45.00 to $50.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Finally, Canaccord Genuity Group increased their target price on 10x Genomics from $60.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. Five analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, 10x Genomics has an average rating of “Hold” and a consensus target price of $68.00.

10x Genomics Company Profile

10x Genomics, Inc is a life sciences technology company that develops tools for analyzing biological systems at the single-cell and spatial levels. Its technologies are designed to help researchers study gene expression, cellular interactions, tissue organization and other biological processes in greater detail than conventional laboratory methods.

The company’s product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial transcriptomics, and the Xenium platform for high-resolution in situ analysis of tissue samples.